Business Context and Reporting Period
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company focused on developing novel treatments for bacterial infections and rare diseases. This Form 10-Q covers the quarterly period ended March 31, 2026. The Company has ceased development of its SPR206 and SPR720 programs, shifting its strategic focus entirely to the tebipenem HBr program in collaboration with GlaxoSmithKline (GSK). GSK has resubmitted the New Drug Application (NDA) for tebipenem HBr, with a Prescription Drug User Fee Act (PDUFA) decision date set for June 18, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $0.3 million | $5.9 million |
| Net Loss | $(7.2) million | $(13.9) million |
| Net Loss Per Share (Basic & Diluted) | $(0.13) | $(0.25) |
| Operating Expenses | $7.8 million | $20.6 million |
| Cash and Cash Equivalents (End of Period) | $56.1 million | $48.9 million |
| Net Cash Provided by Operating Activities | $15.9 million | $(4.0) million |
| Accumulated Deficit | $(458.3) million | $(473.5) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $5.6 million (96%) compared to Q1 2025. This was driven by the cessation of grant revenue (BARDA and NIAID contracts fully utilized or terminated) and a significant reduction in collaboration revenue from GSK as performance obligations were largely satisfied.
- Expense Reduction: Total operating expenses decreased by $12.8 million (62%). Research and Development (R&D) expenses dropped $10.7 million, primarily due to the completion of the pivotal Phase 3 PIVOT-PO trial and the cessation of the SPR720 and SPR206 programs. General and Administrative (G&A) expenses decreased $1.9 million due to reduced headcount and professional fees.
- Improved Cash Flow: The Company generated $15.9 million in net cash from operating activities in Q1 2026, a reversal from the $4.0 million cash burn in Q1 2025. This improvement was primarily due to the receipt of a $25.0 million milestone payment from GSK in February 2026 upon the NDA filing.
- Reduced Net Loss: Net loss improved by $6.7 million year-over-year, reflecting the substantial decrease in operating costs.
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: As of March 31, 2026, the Company held $56.1 million in cash. Management believes this is sufficient to fund operations and capital expenditures into 2028. No additional financing is currently required, though future funding may be needed beyond that horizon.
- Regulatory Milestone: The primary near-term catalyst is the FDA decision on the tebipenem HBr NDA, expected on June 18, 2026. Approval is critical for realizing future commercial milestones and royalties.
- Legal Proceedings: The SEC concluded its investigation into the Company in January 2026 and does not intend to recommend an enforcement action against Spero Therapeutics at this time. Former executives Dr. Ankit Mahadevia and Mr. Satyavrat Shukla settled with the SEC regarding prior disclosures.
- Risk Factors: The Company's prospects are substantially dependent on the tebipenem HBr program and the GSK collaboration. Risks include potential FDA rejection, failure to achieve commercial milestones, and the need for future capital if the current runway is extended or if new programs are pursued.
Investor Verification Checklist
- Verify the status of the FDA review for the tebipenem HBr NDA and the June 18, 2026 PDUFA date.
- Confirm the terms of the GSK License Agreement regarding future commercial milestones ($101 million) and sales milestones ($225 million) contingent on approval and sales thresholds.
- Review the Company's cash burn rate and confirm the "into 2028" liquidity runway assumption given the cessation of other programs.
- Monitor for any updates on the SEC investigation conclusion and potential impacts on future governance or executive compensation.
- Assess the impact of the terminated SPR206 and SPR720 programs on the Company's long-term pipeline diversification strategy.